AstraZeneca plc (NASDAQ:AZN) finally published its full year 2020 results indicating impressive revealing that it managed to achieve double digit growth thanks to its rapidly growing portfolio of new medicines.
The revenue from the company’s product portfolio allowed it to boost its profitability and weather the effects of the pandemic. Astrazeneca achieved the impressive growth thanks to its strategy which includes the sale of medicines to the biopharmaceutical and oncology segments. Some of the company’s fast-selling products include Farxiga and Tagrisso.
Astrazeneca also employed cost-cutting measures as part of its growth strategy during the year. For example, the R&D Expenses dropped by 1% in 2020 compared to the previous year. The total operating expenses dropped by 2%. The reduced expenses contributed to the company’s overall better performance during the year. However, the COVID19 situation limited more sales which would have yielded even better performance.
Targeting growth opportunities in the future
Astrazeneca hopes to deliver a better performance in 2021 and it plans to achieve that by maintaining the same formula that it used in 2020. It will maintain a focus on strong sales from its existing pipeline while also slashing costs. It also plans to invest more money into expanding its sales into more global markets and also expanding its portfolio through new drugs.
The pharmaceutical giant particularly plans to leverage sales from its recently approved coronavirus vaccine. Astrazeneca also plans to acquire Alexion, a move that will be accretive to its commercial and scientific performance. The company has been investing heavily in the creation of new biopharmaceutical and oncology medicines. The idea is to tap into the heavy demand for such therapies in the two segments.
Astrazeneca is also exploring the expanded use of treatments such as Farxiga beyond their indications. For example, its tezepelumab research yielded promising results for Asthma patients. The expanded designations will allow the company to boost its revenue and profitability.